Abstract
Aim: The objective of the present study was to evaluate the role of visfatin in gestational diabetes mellitus. Materials and methods: Forty-five pregnant women at 24 to 28 weeks’ gestation were assigned to consume an initial screening test using a 1-h 50-g glucose load, and then a 3-h 100-g glucose load. The study group consisted of 23 patients who were diagnosed with gestational diabetes mellitus and the control group consisted of 22 healthy pregnant women. We studied the levels of visfatin and the other parameters of inflammation, glucose and lipid metabolism between the 24th and 28th week of gestation and also between the 6th and 10th week after delivery. Results: Plasma visfatin and glucose levels at 60 min after a 50-g and a 100-g glucose load between the 24th and 28th week of gestation were significantly higher in the gestational diabetes group than in the control group. There were no statistical differences in visfatin levels between the groups at 6–10 weeks post-partum. Conclusion: Visfatin levels were significantly elevated in women with gestational diabetes mellitus and during the course of pregnancy and increased visfatin concentrations were reduced within 6 to 10 weeks after delivery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31 (Suppl 1): 55–60.
Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased Visfatin visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110: 605–9.
Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 295–9.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307: 426–30.
Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006, 13: 364–7.
Haider DG, HandisuryaA, Storka A, et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. Diabetes Care 2007, 30: 1889–91.
Szamatowicz J, Kuzmicki M, Telejko B, et al. Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol 2009, 80: 14–8.
American Diabetes Association. Clinical practice recommendations. Gestational diabetes mellitus. Diabetes Care 2002, 25 (Suppl 1): 94–6.
Matthews DR, Hasker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985, 28: 412–9.
Di Cianni G, Seghieri G, Lencioni C, et al. Normal glucose tolerance and gestational diabetes mellitus: what is in between?. Diabetes Care 2007, 30: 1783–8.
Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007, 50: 1033–7.
Mastorakos G, Valsamakis G, Papatheodorou DC, et al. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem 2007, 53: 1477–83.
Akturk M, Altinova AE, Mert I, et al. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 2008, 31: 610–3.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gok, D.E., Yazici, M., Uckaya, G. et al. The role of visfatin in the pathogenesis of gestational diabetes mellitus. J Endocrinol Invest 34, 3–7 (2011). https://doi.org/10.1007/BF03346687
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346687